Envoy Medical (COCHW) EBIT Margin (2022 - 2026)

Envoy Medical has disclosed EBIT Margin across 5 years of filings, most recently posting 15279.49% for Q1 2026.

• EBIT Margin for Q1 2026 came in at 15279.49%, down 417731.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 9881.2% (down 69252.0% YoY), and the FY2025 annual result was 9240.66%, down 68244.0% from the prior year.
• EBIT Margin came in at 15279.49% for Q1 2026 at Envoy Medical, down from 8513.33% in the prior quarter.
• In the past five years, EBIT Margin ranged from a high of 3150.88% in Q3 2022 to a low of 15279.49% in Q1 2026.
• The 5-year median for EBIT Margin is 8277.97% (2024), against an average of 8736.2%.
• Across the five-year window, EBIT Margin surged 745316 bps in 2023 and slumped 471190 bps in 2025, its largest moves.
• Envoy Medical's EBIT Margin stood at 14530.0% in 2022, then soared by 51 bps to 7076.84% in 2023, then plunged by 53 bps to 10830.95% in 2024, then climbed by 21 bps to 8513.33% in 2025, then tumbled by 79 bps to 15279.49% in 2026.
• The last three EBIT Margin figures came in at 15279.49% (Q1 2026), 8513.33% (Q4 2025), and 13590.48% (Q3 2025), per Business Quant data.